Entospletinib
Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk).[1] It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).[2]
 | |
| Clinical data | |
|---|---|
| Other names | GS-9973 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C23H21N7O |
| Molar mass | 411.469 g·mol−1 |
| 3D model (JSmol) | |
| |
References
- "Definition of entospletinib". NCI Cancer Dictionary. National Cancer Institute.
- "Entospletinib - Gilead Sciences". Adis Insight.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.